# US 2017/0283876 A1 · Biomarker rnf6 for colorectal cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0283876 A1
- Document ID: US20170283876A1
- Status: Published application
- Kind: A1
- Application number: 15/085,790
- Filed: 2016-03-30
- Published: 2017-10-05
- Earliest claimed: 2016-03-30
- Assignees: The Chinese University of Hong Kong
- Applicants: The Chinese University of Hong Kong
- Inventors: JUN YU; Joseph Jao Yiu Sung
- Web page: https://patentgrep.com/patent/US20170283876A1

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- G01N 33/57535: of the large intestine, e.g. colon, rectum or anus
- C12Q 2600/118: Prognosis of disease development
- C12Q 2600/158: Expression markers
- G01N 2800/54: Determining the risk of relapse
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention provides a method for diagnosing of colorectal cancer in a subject and a method for determining risk of recurrence of colorectal cancer among colorectal cancer patients by detecting overexpression of the RNF6 gene, which in some cases is due to a higher than normal copy number of the genomic sequence of this gene. A kit and device useful for such methods are also provided. In addition, the present invention provides a method for treating colon cancer by suppressing RNF6 gene expression or activity.

## Claims

### Claim 1

A method for assessing risk for colon cancer in a subject, comprising the steps of:
(a) measuring RNF6 level in a sample taken from the subject,
(b) comparing the RNF6 level obtained in step (a) with a standard control, and
(c) determining the subject, who has an increased RNF6 level compared with the standard control, as having an increased risk for colon cancer.

### Claim 2 (depends on 1)

The method of claim 1Error! Reference source not found., wherein the sample is a colon mucosa sample.

### Claim 3 (depends on 1)

The method of claim 1, wherein the RNF6 level is RNF6 protein level.

### Claim 4 (depends on 1)

The method of claim 1, wherein the RNF6 level is genomic RNF6 DNA level or RNF6 mRNA level.

### Claim 5 (depends on 3)

The method of claim 3, wherein step (a) comprises an immunoassay using an antibody that specifically binds the RNF6 protein.

### Claim 6 (depends on 4)

The method of claim 4, wherein step (a) comprises a polynucleotide amplification reaction.

### Claim 7 (depends on 6)

The method of claim 6, wherein the amplification reaction is a polymerase chain reaction (PCR).

### Claim at position 8

-11. (canceled)

### Claim 12

A method for assessing likelihood of recurrence of colon cancer in a colon cancer patient, comprising the steps of:
(a) measuring RNF6 level in a colon cancer sample taken from the colon cancer patient,
(b) comparing the RNF6 level obtained in step (a) with RNF6 level from another colon cancer sample of the same type obtained from a second colon cancer patient and measured by step (a), and
(c) determining the patient, who has a higher RNF6 level compared with the RNF6 level determined in the other colon cancer sample of the same type obtained from a second colon cancer patient and measured by step (a), as having an increased risk for recurrence of colon cancer compared with the second colon cancer patient.

### Claim 13 (depends on 12)

The method of claim 12, wherein the colon cancer sample is a colon mucosa sample.

### Claim 14 (depends on 12)

The method of claim 12, wherein the RNF6 level is RNF6 protein level.

### Claim 15 (depends on 12)

The method of claim 12, wherein the RNF6 level is genomic RNF6 DNA level or RNF6 mRNA level.

### Claim 16 (depends on 12)

The method of claim 12, wherein step (a) comprises an immunoassay using an antibody that specifically binds the RNF6 protein.

### Claim 17 (depends on 12)

The method of claim 12, wherein step (a) comprises a polynucleotide amplification reaction.

### Claim 18 (depends on 17)

The method of claim 17, wherein the amplification reaction is a polymerase chain reaction (PCR).

### Claim 19 (depends on 18)

The method of claim 18, wherein the PCR is a reverse transcriptase-PCR (RT-PCR).

### Claim 20 (depends on 12)

The method of claim 12, wherein step (a) comprises a polynucleotide hybridization reaction.

### Claim 21 (depends on 12)

The method of claim 12, wherein the patient has previously received treatment for colon cancer.

### Claim 22 (depends on 12)

The method of claim 12, wherein the second patient has an RNF6 level essentially the same as the RNF6 level determined in another colon sample of the same type that is (1) obtained from a healthy individual who does not have colon cancer or an elevated risk for developing colon cancer; and (2) measured by step (a).

### Claim 23

A kit for detecting colon cancer in a subject, comprising (1) a standard control that provides an average amount of RNF6 protein or RNF6 mRNA or an average copy number of RNF6 genomic sequence; and (2) an agent that specifically and quantitatively identifies RNF6 protein, RNF6 mRNA, or RNF6 genomic sequence.

### Claim at position 21

24-29. (canceled)

### Claim 30

A method for inhibiting growth of a colon cancer cell, comprising contacting the colon cancer cell with an effective amount of a neutralizing antibody against RNF6 protein or a nucleic acid encoding a polynucleotide sequence that is complementary to at least a segment of RNF6 mRNA and suppresses RNF6 mRNA expression.

### Claim at position 23

-34. (canceled)
